GlassScriptPhysician profile
Alicia D King
NPI 1104860287
$2,168.63
in general payments reported to CMS, 2019-2025
17 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.16 · 2021: $386 · 2022: $546 · 2023: $553 · 2024: $259 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,138.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $286.84 | 2021-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $274.38 | 2021-2023 | |
| Amgen INC. | $266.47 | 2021-2025 | Otezla, Repatha |
| Abbvie INC. | $219.90 | 2022-2024 | |
| Mylan Specialty L.P. | $218.38 | 2021-2024 | Yupelri |
| Novo Nordisk INC | $217.88 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $211.44 | 2019-2025 | Breztri, Farxiga |
| Pfizer INC. | $132.66 | 2021-2023 | |
| Glaxosmithkline, LLC. | $89.87 | 2021-2024 | Arexvy, Shingrix |
| Astellas Pharma US INC | $88.73 | 2021-2023 | Veozah |
| Janssen Pharmaceuticals, INC | $44.16 | 2023-2024 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.50 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.69 | 2022 | |
| Seqirus USA INC | $20.22 | 2024 | Flucelvax |
| Abiomed | $15.63 | 2024 | Impella |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $14.72 | 2021 | |
| Boston Scientific Corporation | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicia King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.